0000000001265400

AUTHOR

Navid Goodarzi

showing 1 related works from this author

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin

2015

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release solid oral dosage forms containing ribavirin are reviewed. Ribavirin is highly soluble, but its permeability characteristics are not well defined. Therefore according to the Biopharmaceutical Classification System, and taking a “worst case” approach, ribavirin should be assigned to class III. As ribavirin is transported across the brush border membrane of the human jejunum by hCNT2, it shows saturable uptake in the intestine. However, no common excipients have been shown to compete for ribavirin absorption, nor have problems with BE of immediate release rib…

0301 basic medicineDrugribavirinDrug Compoundingvirusesmedia_common.quotation_subjectAdministration OralPharmaceutical ScienceCapsulesPharmacologyBioequivalenceAntiviral Agents030226 pharmacology & pharmacyPermeabilityArticleDosage formExcipients03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTherapeutic indexHumansMedicineImmediate releasemedia_commonbusiness.industrysolubilityRibavirinvirus diseasesbiochemical phenomena metabolism and nutritionBCSbiowaiver030112 virologydigestive system diseasesBiopharmaceuticalTherapeutic EquivalencychemistryManufacturing methodsbusinessabsorptionTabletsJournal of Pharmaceutical Sciences
researchProduct